CD274 and neoplasm: A CRISPR/Cas9 with a single guide RNA (sgRNA) targeting the programmed death‐ligand 1 (PD‐L1) encoding gene (sgPD‐L1) was used to disrupt the immunosuppressive tumor microenvironment and increase the effectiveness of VLN in cancer therapy.